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leled increased enthusiasm among thoracic surgeons for
homografts as replacement valve conduits for the
reconstruction of the pulmonary outflow ventricle.2-5
Although the results of cryopreserved homograft
valves for reconstruction of the right ventricular out-
flow tract in complex congenital heart diseases has been
reported by several previous authors,5-13 reports on
medium-term follow-up are still uncommon.14,15 We
reviewed our experience since 1985 with 331 patients,
including Ross operations, in whom cryopreserved
homografts were used in the “pulmonary” position to
examine the risk factors associated with homograft fail-
ure over the mid-term follow-up period.
Methods
A homograft was first used to reconstruct the pulmonary
outflow tract at the Oklahoma University Health Sciences
T he use of homograft valves to reconstruct the rightventricular outflow tract was introduced by Ross and
Somerville1 in 1966. Refinements in the harvesting, cryo-
preservation, and distribution of homografts have paral-
Objective: The purpose of this study was to examine the durability of cryo-
preserved homografts used to replace the “pulmonary” valve and to
identify factors associated with their late deterioration. Methods: We
reviewed our entire experience (1985-1997) with 331 survivors in whom
cryopreserved homograft valves (pulmonary, n = 304; aortic, n = 27)
were used to reconstruct the pulmonary outflow tract. Median age was
14 years (range, 2 days–62 years). Operations included Ross operation
(n = 259), tetralogy of Fallot (n = 41), truncus arteriosus (n = 14),
Rastelli operation (n = 11), and others (n = 6). Median follow-up was 3.8
years (range, 0.2–11.2 years); late echographic follow-up was complete
for 97% of patients. Homograft failure was defined as the need for
explantation and valve-related death; homograft dysfunction was
defined as a pulmonary insufficiency grade 3/4 or greater and a trans-
valvular gradient of 40 mm Hg or greater. Results: Homograft failure
occurred in 9% (30 of 331 patients; Kaplan-Meier); freedom from fail-
ure was 82% ± 4% at 8 years. Homograft dysfunction occurred in 12%
(39 of 331 patients), although freedom from dysfunction was 76% ± 4%
at 8 years. For aortic homografts, this was 56% ± 11%, compared to
80% ± 4% for pulmonary homografts (P = .003). For patients aged less
than 3 years (n = 38), this was 51% ± 12%, compared with 87% ± 4%
for older patients (P = .0001). By multivariable analysis, younger age of
homograft donors, non-Ross operation, and later year of operation were
associated with homograft failure; younger age of homograft donors,
later year of operation, and use of an aortic homograft were associated
with homograft dysfunction. Conclusions: Homograft valves function sat-
isfactorily in the pulmonary position at mid-term follow-up. The pul-
monary homograft valve appears to be more durable than the aortic
homograft valve in the pulmonary position. (J Thorac Cardiovasc Surg
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Center in November 1985. Through January 1997, this recon-
struction was performed in 369 patients, with 38 early deaths.
The 331 patients surviving to hospital discharge form the
basis of this review. Patients who had homograft tissue used
only as a nonvalved patch are not included. In all cases the
homografts were prepared by CryoLife Inc (Kennesaw, Ga).
Patient characteristics. The median age at operation of
the 237 male patients and 94 female patients was 14 years
(range, 2 days–62 years). The homografts were used as part
of the following operations: Ross operation (n = 259; 78%),
tetralogy of Fallot or pulmonary atresia with ventricular sep-
tal defect (n = 41; 13%), truncus arteriosus (n = 14; 4%),
Rastelli-type operation (n = 11; 3%), and others (n = 6; 2%).
One hundred eighty patients (54%; 180 of 331 patients) had
undergone previous cardiac operations, 46 (14%) of which
were on the pulmonary outflow tract. Twenty-one patients
had a previous right ventricular outflow tract (RVOT) recon-
struction with a homograft, and 5 patients had a previous aor-
tic valve replacement with a homograft.
Homograft characteristics. Twenty-seven aortic homo-
grafts and 304 pulmonary homografts were used. The medi-
an age of the homograft donors was 19 years (range, 5
months–58 years). The homografts varied in size from 10 to
30 mm in diameter (mean, 22.4 ± 4.1 mm). The mean time
period between harvesting and implantation of the homo-
grafts was 7.7 ± 8.4 months (duration of cryopreservation).
Patient follow-up. The medical records of the 331 patients
included in this study were reviewed to obtain detailed infor-
mation on the operation, previous intervention, subsequent
need for operative treatment, and physical status. Homograft
status was evaluated by 2-dimensional, color flow, and con-
tinuous wave Doppler echocardiography. The pressure gradi-
ent across the RVOT was measured by peak instantaneous
Doppler velocity with pulse and continuous wave Doppler
techniques. Peak flow velocities were obtained from the
Doppler tracings and converted to peak instantaneous gradi-
ents by a simplified Bernoulli test. Homograft regurgitation
was graded subjectively as 0 to 4, with 3+ or greater repre-
senting significant regurgitation. Follow-up ranged from 1
month to 11.2 years (median follow-up, 3.8 years).
Definitions of end points. Homograft failure was defined
as all reoperations involving explantation of the homograft
and all valve-related deaths.12,15 Moderate (3+) pulmonary
insufficiency and transvalvular gradient greater than 40 mm
Hg were defined as homograft dysfunction.12,16 The distribu-
tion of outcomes with diagnosis groups is shown in Table I.
There were relatively few patients at risk of conduit failure or
dysfunction beyond 8 years of follow-up; hence most data are
reported as 8-year follow-up.
Statistical analysis. All analyses were performed with
SAS System software (version 6.10; SAS Institute, Cary,
NC). Mean values are presented ± 1 SD. Between-group dif-
ferences of continuous variables were analyzed with analysis
of variance methods, and c 2 or Fisher’s exact methods were
used to test differences between proportions. Actuarial esti-
mates of freedom from postoperative events were accom-
plished with Kaplan-Meier methods, and P values for differ-
ences between distributions were obtained by log-rank
testing. Event-free rates are presented with ± 1 SE of the esti-
mate. Potential risk factors evaluated in multivariable analy-
sis of conduit failure or dysfunction included age, weight,
sex, date of operation, diagnosis, previous cardiac operations,
previous homograft, type of homograft (either aortic or pul-
monary), size of homograft, duration of cryopreservation,
and age of homograft donor. The analyses were performed
with Cox proportional hazards regression. A forward step-
wise selection method was used to add variables to the model,
requiring significance at P < .10 for entry and P < .05 for
retention in the model. Early death was defined as hospital
death or death within 30 days after operation. 
Results
The late mortality rate was 4% (13 of 331 patients).
Of these, only 2 deaths were valve-related, yielding a
late valve-related mortality rate of 1%. Both late deaths
were related to reoperation, the first occurring in a 2-
year-old child who underwent double homograft
replacement for truncus arteriosus as a neonate, and the
second in a 3-year-old child with pulmonary atresia
and ventricular septal defect who died 2 months after
the operation of mediastinitis after replacement of the
homograft. The 11 nonvalve-related deaths resulted
from chronic heart failure (n = 5), aspiration pneumo-
nia (n = 2), reoperation for unrelated defects, and other
causes such as cerebral aneurysm, myocardial infarc-
tion, suicide, and accidents. 
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Table I. Diagnosis and homograft outcome
No. Valve related Reoperation Obstruction 
Operation of patients late death of conduit (>40 mm Hg)
Ross operation 259 0 14 24
Complex tetralogy of Fallot/ 41 1 7 6
pulmonary atresia with VSD
Truncus arteriosus 14 1 6 5
Transposition of great vessels 11 0 3 4
Other 6 0 0 0
VSD, Ventricular septal defect.
Thirty-nine patients had evidence of homograft dys-
function; of those, 29 have had the homografts re-
placed. One additional patient had the homograft
replaced after an inadvertent injury during an unrelated
cardiac operation. Forty patients (12%) therefore had
either homograft dysfunction or conduit failure. 
Homograft failure. Homograft failure occurred in
30 patients (9%; 30 of 331 patients). These include the
2 valve-related deaths. The indications for explanting
the homografts were conduit stenosis in 23 patients,
homograft insufficiency associated with distal pul-
monary artery stenosis in 3 patients, homograft hood
aneurysms in 2 patients, technical error in 1 patient,
and injury of the homograft during repair of an auto-
graft in 1 patient. Kaplan-Meier freedom from homo-
graft failure was 90% ± 2% at 5 years and 82% ± 4%
at 8 years (Fig 1). This was 89% ± 4% for patients hav-
ing a Ross operation at 8 years versus 62% ± 9% for all
other patients (P = .0001). At 8 years, freedom from
failure was 86% ± 4% for pulmonary homografts ver-
sus 61% ± 11% for aortic homografts (P = .003). 
By univariate analysis, younger age of recipients,
smaller homograft size, and aortic homografts were
significant risk factors; however, by multivariable
analysis only younger donor age (less than 5 years),
later year of operation, and non-Ross operation were
associated with homograft failure (Table II).
Homograft dysfunction. Thirty-nine patients had
evidence of significant homograft obstruction or
incompetence (gradient of 40 mm Hg or more and/or 3-
4+ regurgitation for an incidence of homograft dys-
function of 12%; 39 of 331 patients). Of these, 29 have
had the homografts replaced and are therefore also
included among the homograft failures. Kaplan-Meier
freedom from homograft dysfunction was 90% ± 2% at
5 years and 76% ± 4% at 8 years (Fig 2). This was 84%
± 4% for patients having a Ross operation versus 53%
± 10% for all other patients (P = .006; Fig 3). Kaplan-
Meier freedom from dysfunction at 8 years was 80% ±
4% for pulmonary homografts versus 56% ± 11% for
aortic homografts (P = .006; Fig 4). In 293 patients
older than 3 years, Kaplan-Meier freedom from dys-
function was 81% ± 4% at 8 years, compared with 42%
± 14% for 38 younger patients (P = .005; Fig 5). For
patients aged 18 to 40 years, the freedom from homo-
graft dysfunction at 8 years was 82%.
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Fig 1. Kaplan-Meier freedom from failure (explantation of
homograft or valve-related death). Vertical bars represent the
70% confidence interval.
Fig 2. Kaplan-Meier freedom from dysfunction (>40 mm Hg
homograft obstruction and/or 3-4+ regurgitation). Vertical
bars represent the 70% confidence interval. 
Table II. Risk factors for homograft failure
Multivariable odds ratio 
Characteristic Univariable P value Multivariable P value (95% confidence interval)
Donor age, <5 y .0001 .0001 7.8 (3.3-18.2)
Later year of operation .20 .0343 1.3 (1.1-1.6)
Non-Ross operation .0001 .0058 3.4 (1.4-8.1)
Age of patient (younger) .008 — —
Homograft diameter (smaller) .001 — —
Aortic homograft .003 — —
Although non-Ross operation, use of an aortic homo-
graft, and younger patient age were associated with
homograft failure by univariate analysis, by multivari-
able analysis the use of an aortic homograft, younger
donor age, and later year of operation were the only
risk factors for homograft dysfunction (Table III). Even
when recipient age was forced into the model, donor
age was still a highly significant risk factor, although
recipient age was not.
Discussion
With the increased availability of homografts made
possible by cryopreservation5,18,19 and the development
of valve banks, there has been renewed interest in the use
of the valved homograft to reconstruct the pulmonary
outflow tract. By the mid-1980s, cryopreserved homo-
graft valves were considered by many surgeons to be the
valve conduit of choice for replacement of the pulmonary
valve, because they seemed to have many advantages
over alternative prosthetic valved conduits.2,5-7,12-15,20,21
These advantages include (1) technical ease of implanta-
tion because they are soft and mold easily with the
patient’s cardiac tissue,22 resulting in better hemostasis in
complex operations21,23; (2) better hemodynamics than
porcine-valved Dacron conduits, which improves right
ventricular function after the operation5,7,21,23-25; and (3)
the branches of the homografts may be used to patch dis-
tal pulmonary artery stenoses.7,20,26
As the Ross operation (pulmonary autograft replace-
ment of the aortic valve) has gained popularity, so too
has the use of the pulmonary homograft to reconstruct
the RVOT in this patient population.3,4 In fact, most of
our patients fall into this category. Patients having a
Ross operation generally have normal pulmonary vas-
cular anatomy and resistance, and this may account for
the better late results with pulmonary homografts in
these patients. In contrast, many patients with other
forms of congenital heart disease have distal pul-
monary artery branch stenoses or high pulmonary vas-
cular resistance, both of which may affect the durability
of the homografts.7,27,28 In fact, younger recipient
age,8,12,13 use of the aortic homograft,7,12,15 small
homograft valve size,13 long aortic crossclamp time at
operation,15 pulmonary hypertension,27 and distal pul-
monary artery disease7,28 have all previously been iden-
tified as risk factors associated with medium-term fail-
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Fig 3. Kaplan-Meier freedom from homograft dysfunction,
stratified according to type of procedure (P = .006). Vertical
bars represent the 70% confidence interval. 
Fig 4. Kaplan-Meier freedom from homograft dysfunction,
stratified according to homograft materials (P = .006).
Vertical bars represent the 70% confidence interval. 
Fig 5. Kaplan-Meier freedom from homograft dysfunction,
stratified according to age (P = .005). Vertical bars represent
the 70% confidence interval.
ure of cryopreserved homografts in the RVOT. Young
age at operation seems to be a common risk factor of
the homograft failure,8,12,13 because this closely relates
to the size of the homograft implanted and therefore to
the age of the homograft donor. In addition, infants
generally triple their size within 18 months, thus out-
growing their homograft more quickly than older chil-
dren. This was confirmed in our univariate analysis of
homograft dysfunction by age (Fig 5). However, in our
multivariable analysis young patient age (<3 years) was
not associated with an increased risk of failure.
It is interesting to speculate that younger donor age is
somehow related to increased immunogenicity of the
homograft and that this may have negatively affected
the late function of the homograft; the strong associa-
tion of young donor age in our multivariable analysis
adds support to this theory. Furthermore, severe homo-
graft valved conduit stenosis developed within the first
postoperative year in a few patients who underwent the
Ross operation.29,30 The stenosis was usually located
just above the commissures in the proximal portion of
the homograft conduit. One additional patient experi-
enced the development of rapid homograft deteriora-
tion within 4 months of reoperation for such an
obstruction. These findings lend some credence to a
possible immune-mediated response, 17 although this
speculation remains unproved.31-33 It is possible that
some form of perioperative immunosuppression may
be beneficial in these high-risk patients.17,30
Although aortic homografts have been used to recon-
struct the pulmonary outflow tract for many years,2,5,20
the aortic valves have been considered to be susceptible
to higher rates of calcification in the pulmonary position
than the pulmonary homograft valves because of their
higher elastin and intrinsic calcium content.34 The
Mayo Clinic group12 recently reported that, in the pul-
monary position, the pulmonary homograft was more
durable than the aortic homograft valves with less calci-
fication and obstruction, especially among children 4
years of age or younger. Our study, in which the aortic
homograft was shown to be an independent risk factor
for homograft dysfunction, confirms their findings.
Technical factors such as hood extension of the prox-
imal suture line, anatomic versus nonanatomic place-
ment of the conduit, and compression of the conduit
behind the sternum may all be important determinants
of homograft longevity.12 These were not specifically
analyzed in our study because of the limited number of
such procedures. We did not identify individual cardiac
diagnoses or operative procedures within the non-Ross
operation group of patients as significant risk factors.
Rather, all the congenital cardiac disease subgroups
were collectively associated with increased risk com-
pared with the patients having a Ross operation.
Later year of operation was associated with increased
risk both of homograft failure and homograft dysfunc-
tion. We are unable to explain this finding within the
context of our present study but are further analyzing
patient factors and preservation and biocompatibility
factors in an attempt to resolve this dilemma. 
In summary, for RVOT reconstruction, non-Ross pro-
cedure, cryopreserved aortic homograft valves, homo-
graft valves from younger donors, and later operation
were significant risk factors for homograft failure. The
cryopreserved pulmonary homograft valve appears to
be the conduit of choice for RVOT reconstruction. 
The authors thank Carolyn McCue, RN, and Mark Jones,
PA, who helped with patient review and follow-up, and Karen
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Discussion
Dr Gordon K. Danielson (Rochester, Minn). Most of the
conclusions from this study are in agreement with those of
our recent review of a similar-sized series reported in 1995
and those of other recent reviews of homografts. These find-
ings include the fact that aortic homografts do calcify and
become obstructed faster than pulmonary homografts. 
However, when we reanalyzed our data and included all
reasons for conduit replacement such as false aneurysms of
the anastomotic sites, nearly all of which were associated
with pulmonary homografts in patients with right ventricu-
lar hypertension, we found that there really was no differ-
ence in late failure at least through 4 years. So, the failure
rate depends a little bit on one’s definition of homograft
failure. 
You presented an interesting new set of data that showed
that the incidence of homograft failure was less in patients
after the Ross procedure as compared with other operations
for congenital cardiac anomalies. This may explain, in part,
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the difference between the behavior of pulmonary homo-
grafts in our series compared with yours. Can you discuss the
reasons why there is a difference in homograft failure be-
tween Ross and non-Ross operations?
There was no mention of balloon dilatation or stenting for
homograft stenosis. This does seem to be a problem in some
series. Was this done in any patients in your series and were
such patients included as having homograft dysfunction?
The pulmonary autograft procedure remains controversial.
In some excellent institutions, few if any such operations are
currently performed especially in adults, because of the addi-
tional complexity of the procedure, because of the fact that 2
cardiac valves are put at risk instead of 1, and, until recently
with reports such as yours, because of the lack of data regard-
ing late results of cryopreserved homografts in the pulmonary
position. In other excellent institutions, the Ross procedure is
a treatment of choice.
In view of recent reports of up to 90% or more of patients
being free of reoperation for homograft failure 10 years after
isolated homograft replacement of the aortic valve (especially
patients treated with the current trend toward intraluminal
cylinder or root replacement rather than use of a scalloped
homograft), together with the 16% incidence of incompetent
right ventricle–pulmonary artery homografts, homograft dys-
function, or homograft replacement at 8 years after the Ross
procedure in your series, what are your current thoughts on
the relative role of the Ross procedure in the treatment of aor-
tic valve disease? 
Dr Knott-Craig. With regard to the first question, that the
failure rate and the structural deterioration rate is lower in
patients who have Ross operations versus the other patholo-
gies relates mainly to the fact that patients having isolated
aortic valve replacement have normal distal pulmonary artery
vasculature both in terms of pulmonary hypertension and in
distal embolization problems. 
In terms of balloon dilatation of the pulmonary homografts,
this is not a favored technique in our institution. We have a very
low threshold to replace homografts rather than have the cardi-
ologists address them either with stents or balloon dilatations. 
The question about the Ross operation is a little beyond the
scope of my presentation. However, generally speaking,
when any new operation is adopted by a wide variety of sur-
geons with varying expertise, the indications become diluted
and complications can be anticipated, resulting in reopera-
tions on the aortic valve or pulmonary valve. However, the
alternatives available in young children and infants remain
limited, and this is the area where the Ross operation has its
greatest aptitude.
Dr Charles A. Yankah (Berlin, Germany). The group in
Berlin has done over 300 homograft implantations in the
RVOTs. Since 1986 we have known that the pulmonary
homograft is the valve of choice and that it is a better alter-
native. The question is whether a viable homograft will be
suitable for children, especially, because our immunologic
problem with homovital cryopreserved homografts, which
were used mainly in infants and in children, subsequently
yielded no satisfactory results. The pathologic condition of
the homograft explants was either at the valvular level with
degenerative stenosis or at the supravalvular level. Did you
observe such pathologic changes with regard to multilevel
stenosis, which we observed especially in our children? With
regard to your experience, would you derive any suggestion
for preferring a nonviable homograft in infants and children,
rather than homovital or viable homografts?
Dr Knott-Craig. If one tries to define why later year of
operation was a risk factor for dysfunction or failure and why
younger donor age was a risk factor for both failure and dys-
function, there are limited alternative explanations. We think
that immunogenicity is important and is more important the
younger the patient. We tried to define this better in our
analysis by looking at the duration of cryopreservation from
harvesting to the implantation of the homograft. Although
this seemed important, it never stood up in the multivariate
analysis as an independent risk factor for failure. We have
also seen early homograft failure particularly in young chil-
dren. Currently, if this should occur within 1 year of the oper-
ation, we put the patient on high-dose ibuprofen or steroids
for the first 3 months after the operation. So yes, I think via-
bility of the cells is an issue in children, but we have not yet
defined how to deal with it. 
Dr Lawrence H. Cohn (Boston, Mass). I have one very
short question. This is a fantastic series. For those of us who
do this in young adults, can you give us any estimate of the
freedom of homograft dysfunction at 8 years in patients who
are 18 years or older when you do this operation?
Dr Knott-Craig. In the age group 18 to 40 years, the free-
dom from homograft dysfunction is about 82% at 8 years, not
statistically different from the 0- to 18-year age group.
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